Pomerantz LLP Targets Nektar and Enphase in New Securities Class Actions

The legal landscape for high-growth sectors is shifting as Pomerantz LLP, a powerhouse in securities litigation, moves forward with class action lawsuits against Nektar Therapeutics (NKTR) and Enphase Energy (ENPH). These filings, announced in late March 2026, represent a significant escalation in the regulatory and legal pressures facing companies in the biotechnology and renewable energy industries. While the specific allegations vary, the underlying theme remains consistent: a claim that these entities failed to provide transparent disclosures to investors, leading to significant financial losses when negative news eventually surfaced.

For Nektar Therapeutics, the litigation follows a period of intense volatility common in the biopharmaceutical sector. Historically, Nektar has faced scrutiny over the transparency of its clinical trial data, most notably regarding its partnership with Bristol-Myers Squibb for the BEMPEG program. In the current context, the class action likely centers on whether the company’s leadership provided an overly optimistic outlook on its pipeline development or failed to disclose material risks associated with its ongoing trials. In the biotech world, where a single FDA decision or trial result can wipe out billions in market capitalization, the line between 'forward-looking optimism' and 'misleading statements' is frequently litigated. Pomerantz’s move suggests they have identified specific discrepancies in Nektar’s public statements that they believe meet the high threshold for securities fraud.

“

The legal landscape for high-growth sectors is shifting as Pomerantz LLP, a powerhouse in securities litigation, moves forward with class action lawsuits against Nektar Therapeutics (NKTR) and Enphase Energy (ENPH).

Simultaneously, the action against Enphase Energy underscores the legal risks inherent in the rapidly evolving renewable energy market. Enphase, a leader in solar microinverter technology, has been navigating a complex macroeconomic environment characterized by fluctuating interest rates and shifting regulatory frameworks, such as California’s NEM 3.0. The lawsuit likely targets the company’s disclosures regarding inventory levels and demand forecasting. In previous cycles, solar companies have faced legal challenges when they failed to accurately report inventory gluts in international markets or when their revenue recognition practices were called into question. For Enphase, which has been a darling of ESG-focused portfolios, this litigation could signal a period of increased skepticism from institutional investors who demand greater clarity on supply chain health and regional demand trends.